Head & Neck Squamous Cell Carcinoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

FID-007 Plus Cetuximab Demonstrates Encouraging Activity in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

06/05/2026

Guilherme Rabinowits, MD

Guilherme Rabinowits, MD, discusses results from a phase 2 trial which demonstrated that FID-007 plus cetuximab showed promising activity and manageable safety in patients with recurrent or metastatic head and neck squamous cell carcinoma who...

Guilherme Rabinowits, MD,...

06/05/2026

Oncology

Videos

ASP-1929 Photoimmunotherapy Demonstrates Clinical Benefit in Recurrent Head and Neck Squamous Cell Carcinoma

06/05/2026

Anastasios Maniakas, MD, PhD

Anastasios Maniakas, MD, PhD, discusses results from a phase 3 study which found that ASP-1929 photoimmunotherapy improved response and quality-of-life outcomes in recurrent head and neck squamous cell carcinoma.

Anastasios Maniakas, MD, PhD,...

06/05/2026

Oncology

Videos

Amivantamab Demonstrates Durable Responses in HPV-Unrelated Head and Neck Squamous Cell Carcinoma

06/05/2026

Barbara Burtness, MD, FASCO

Barbara Burtness, MD, FASCO, discusses phase 2 OrigAMI-4 results showing that subcutaneous amivantamab achieved a 47% response rate in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma after progression on...

Barbara Burtness, MD, FASCO,...

06/05/2026

Oncology

Videos

Emi-Le Demonstrates Promising Activity in Aggressive Adenoid Cystic Carcinoma

06/01/2026

Glenn Hanna, MD

Glenn Hanna, MD, discusses promising phase 1 results for emiltatug ledadotin (Emi-Le; XMT-1660), a novel B7-H4-directed antibody-drug conjugate that demonstrated encouraging efficacy and a favorable safety profile in patients with aggressive...

Glenn Hanna, MD, discusses...

06/01/2026

Oncology

Videos

Metabolic Subtyping Predicts Immunotherapy Response in Nasopharyngeal Carcinoma

05/13/2026

Sai-Wei Huang, MD

Sai-Wei Huang, MD, discusses findings from a study evaluating metabolic biomarkers in patients with nasopharyngeal carcinoma using RNA sequencing.

Sai-Wei Huang, MD, discusses...

05/13/2026

Oncology

Videos

Using ctDNA to Guide Treatment in HPV-Positive Oropharyngeal Cancer

04/29/2026

Catherine Haring, MD

Catherine Haring, MD, discusses findings from a study evaluating ctDNA as a biomarker in patients with HPV-related oropharyngeal cancer undergoing surgery.

Catherine Haring, MD, discusses...

04/29/2026

Oncology

Videos

Risk of Osteoradionecrosis in Patients With Oral Cavity Cancer Undergoing Radiation Therapy

03/17/2026

Annu Singh, MD

Annu Singh, MD, discusses results from a retrospective cohort study comparing incidence of late-term osteoradionecrosis in patients with oral cavity cancer undergoing intensity-modulated and proton radiation therapy.

Annu Singh, MD, discusses...

03/17/2026

Oncology

Videos

Radiation Modality Influences Risk of Osteoradionecrosis in Head and Neck Cancer

03/17/2026

Edward Christopher Dee, MD

Edward Christopher Dee, MD, discusses results from a retrospective cohort study evaluating osteoradionecrosis risk in patients with oropharyngeal cancers treated with either proton or intensity-modulated radiation therapy.

Edward Christopher Dee, MD,...

03/17/2026

Oncology

Videos

First-Line Amivantamab Plus Pembrolizumab in HPV-Negative Head and Neck Squamous Cell Carcinoma

03/05/2026

Ranee Mehra, MD

Ranee Mehra, MD, discusses results from cohort 2 of the phase 1b/2 OrigAMI-4 study, which evaluated first-line subcutaneous amivantamab plus pembrolizumab in HPV-negative, PD-L1–positive head and neck squamous cell carcinoma.

Ranee Mehra, MD, discusses...

03/05/2026

Oncology

Videos

Tumor-Informed ctDNA MRD Assay May Predict Recurrence and Survival Outcomes in HPV-Independent Head and Neck Cancer

03/05/2026

Thomas Roberts, MD, MBA

Thomas Roberts, MD, shared study results which analyzed a tumor-informed ctDNA-based MRD assay in primarily HPV-independent, locally advanced head and neck squamous cell carcinoma.

Thomas Roberts, MD, shared study...

03/05/2026

Oncology

Recent News

News

Trastuzumab Rezetecan Improves Progression-Free Survival in Previously Treated HER2-Positive Metastatic Breast Cancer

07/10/2026

Stephanie Holland

Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...

Interim results from the phase...

07/10/2026

Oncology

FDA Approval

FDA Approves Subcutaneous Isatuximab Across Multiple Indications for Patients With Multiple Myeloma

07/10/2026

Emily Estrada

The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.

The FDA has approved...

07/10/2026

Oncology

News

Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer

07/09/2026

Stephanie Holland

A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...

A multicenter real-world study...

07/09/2026

Oncology

News

Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer

07/09/2026

Stephanie Holland

Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...

Results from the phase 3 ELEVATE...

07/09/2026

Oncology

FDA Alerts

FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors

07/09/2026

Emily Estrada

The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...

The FDA accepted the new drug...

07/09/2026

Oncology

News

Brain Radiotherapy Plus Continued Systemic Therapy Improves Survival in Brain-Only Progressive Extensive-Stage Small Cell Lung Cancer

07/09/2026

Stephanie Holland

Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...

Results from a multicenter...

07/09/2026

Oncology

News

Dose-Escalation Study Supports Phase 2 Development of BMS-986205 Plus Radiotherapy and Nivolumab in Glioblastoma

07/09/2026

Stephanie Holland

Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...

Results from a phase 1 trial...

07/09/2026

Oncology

News

First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia

07/09/2026

Stephanie Holland

Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...

Results from the ongoing, phase...

07/09/2026

Oncology

News

Imetelstat Maintains Overall Survival Advantage Over Best Available Therapy in JAK Inhibitor–Relapsed or Refractory Myelofibrosis

07/09/2026

Stephanie Holland

Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...

Updated results from a post hoc...

07/09/2026

Oncology

News

Aglatimagene Plus Radiotherapy Improves Disease-Free Survival in Localized Prostate Cancer

07/09/2026

Emily Estrada

Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...

Results from the phase 3 PrTK03...

07/09/2026

Oncology